Figure 10.
(a) Design strategy of dual β-secretase (BACE-1)/ glycogen synthase kinase 3 (GSK-3β) inhibitors that combines the pharmacophoric features for the BACE-1 and GSK-3β binding; (b,c) chemical structures of the most promising derivatives. Adapted from [107].